| Harnessing the immune response to treat cancer. | |
| | |
MedLine Citation:
|
PMID: 20856204 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It is well established that the immune system has the capacity to attack malignant cells. During malignant transformation cells acquire numerous molecular and biochemical changes that render them potentially vulnerable to immune cells. Yet it is self-evident that a growing tumour has managed to evade these host defence mechanisms. The exact ways in which the immune system interacts with tumour cells and how cancers are able to escape immunological eradication have only recently started to be fully elucidated. Understanding the relationship between the tumour and the anti-tumour immune response and how this can be altered with conventional treatments and immune-targeted therapies is crucial to developing new treatments for patients with cancer. In this review, focusing on the anti-tumour T-cell response, we summarize our understanding of how tumours, cancer treatments and the immune system interact, how tumours evade the immune response and how this process could be manipulated for the benefit of patients with cancer. |
| | |
Authors:
|
H J Steer; R A Lake; A K Nowak; B W S Robinson |
Related Documents
:
|
15550144 - Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma i... 17925864 - The chemokine receptor cxcr4 strongly promotes neuroblastoma primary tumour and metasta... 21239534 - Lps-induced decrease in intracellular labile zinc, [zn]i, contributes to apoptosis in c... 19212434 - Dual role of sp3 transcription factor as an inducer of apoptosis and a marker of tumour... 15072464 - Caspase-1 mediates fas-induced apoptosis and is up-regulated by interferon-gamma in hum... 11466394 - Administration of pentoxifylline during allergen sensitization dissociates pulmonary al... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-09-20 |
Journal Detail:
|
Title: Oncogene Volume: 29 ISSN: 1476-5594 ISO Abbreviation: Oncogene Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-02 Completed Date: 2011-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8711562 Medline TA: Oncogene Country: England |
Other Details:
|
Languages: eng Pagination: 6301-13 Citation Subset: IM |
Affiliation:
|
School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia. hsteer@meddent.uwa.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigen-Presenting Cells
/
physiology Antigens, Neoplasm / immunology Apoptosis CD8-Positive T-Lymphocytes / immunology Humans Immunotherapy Lymphocyte Activation Neoplasms / immunology*, pathology, therapy* Tumor Escape |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, Neoplasm |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
Next Document: RBP-J?-dependent Notch signaling enhances retinal pigment epithelial cell proliferation in transgeni...